

Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

June 12, 2007 6:30 – 9:00 p.m.

1.	Executive Session Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreeme (as provided by 33 VSA § 1998(f)(2))	6:30 - 7:00 ents
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	OVHA Pharmacy Administration Updates	7:05 - 7:15
4.	Medical Director Update	7:15 - 7:25
5.	Follow-up Items from Previous Meeting Methadone FDA Alert Capital® w/codeine Ophthalmics: Wetting Agents	7:25 - 7:35
6.	Clinical Update: Drug Reviews (Public comment prior to Board action) Invega® (paliperidone) Lyrica® (pregabalin) Abilify® (ariprazole) Injection – Abbreviated Review	7:35 – 7:50
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action) Pulmonary: Antihistamines 1 st and 2 nd Generation Rheumatoid and Psoriatic Arthritis Injectables Ankylosing Spondylitis Injectables Psoriasis Injectables Ulcerative Colitis Injectables Crohn's Injectables Synagis® Antipsychotics: Atypical and Combination Antipsychotics: Typical Andipressants: Novel (automated step therapy)	7:50 – 8:25

8.	Drug Classes – New Miscellaneous: (Botox)	8:25 – 8:35
	 Compounded Products: Bioidentical/Individualized Hormonal 	Products
9.	RetroDUR Long Acting Narcotics Acetaminophen > 4 grams/day	8:35 - 8:45
10.	Updated New-to-Market Drug Monitoring Log	8:45 - 8:50
11.	General Announcements Rosiglitazone	8:50 - 9:00
12.	Adjourn	9:00